感染

订阅

MedSci主页 / 所有栏目 / 感染

Lancet oncol：精神病患者中艾滋、乙肝和丙肝的发病率和风险因子

2017-07-05 MedSci MedSci原创

精神病艾滋乙肝丙肝
关注

精神病患者中艾滋、乙肝和丙肝的发病率和风险因子

精神病患者中艾滋、乙肝和丙肝的发病率和风险因子

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829060, encodeId=3e771829060e7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 25 18:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864994, encodeId=a023186499433, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 02 19:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823357, encodeId=0ea6182335e94, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jul 16 01:00:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042451, encodeId=cd972042451e5, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jun 13 00:00:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529257, encodeId=d604152925e17, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Fri Jul 07 01:00:00 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2017-08-25 howi

    #Lancet#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1829060, encodeId=3e771829060e7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 25 18:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864994, encodeId=a023186499433, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 02 19:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823357, encodeId=0ea6182335e94, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jul 16 01:00:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042451, encodeId=cd972042451e5, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jun 13 00:00:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529257, encodeId=d604152925e17, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Fri Jul 07 01:00:00 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2018-03-02 minlingfeng

    #Oncol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1829060, encodeId=3e771829060e7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 25 18:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864994, encodeId=a023186499433, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 02 19:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823357, encodeId=0ea6182335e94, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jul 16 01:00:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042451, encodeId=cd972042451e5, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jun 13 00:00:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529257, encodeId=d604152925e17, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Fri Jul 07 01:00:00 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2017-07-16 lifestar

    #发病率#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829060, encodeId=3e771829060e7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 25 18:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864994, encodeId=a023186499433, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 02 19:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823357, encodeId=0ea6182335e94, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jul 16 01:00:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042451, encodeId=cd972042451e5, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jun 13 00:00:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529257, encodeId=d604152925e17, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Fri Jul 07 01:00:00 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2018-06-13 医者仁心

    #精神病患者#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829060, encodeId=3e771829060e7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 25 18:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864994, encodeId=a023186499433, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 02 19:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823357, encodeId=0ea6182335e94, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jul 16 01:00:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042451, encodeId=cd972042451e5, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jun 13 00:00:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529257, encodeId=d604152925e17, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Fri Jul 07 01:00:00 CST 2017, time=2017-07-07, status=1, ipAttribution=)]
    2017-07-07 cenghis

    #风险因子#

    0

相关资讯

曹庆久：与精神病患儿沟通 术重要心更重要

正常人之间的沟通有时都是“鸡对鸭讲“，与精神病患者沟通那就更是难上加难了，尤其是儿童患者。北京大学第六医院儿童病房主任、副主任医师曹庆久就基本做到了与精神病患儿的顺畅沟通。他是如何做到的呢？

Lancet Psychiat：在精神病患者中实施禁烟政策会导致暴力事件增加吗？

禁烟政策对于保护健康消除健康不公平有重要作用。对于在精神病院全面开展禁烟政策的一个主要障碍是工作人员担心禁烟会导致暴力事件增加。

Nat Genet：RBM12基因截断突变导致精神病

研究人员采用全基因组测序和长距离定位对一个冰岛家族进行研究，其中包括十个患有精神类疾病（精神分裂症，分裂情感性障碍或精神病性躁郁症）的个体。我们发现所有患病个体都携带RBM12（RNA结合基序蛋白12）上的c.2377G> T突变（P = 2.2×10-4），这是一个会导致RNA识别motif缺失并产生截短蛋白的无义突变。

Neuropsychopharmacology：大麻衍生物有助于治疗精神病

一项最新研究通过检测大麻化合物对大鼠的影响，为开发精神分裂症新疗法铺平了道路。这项研究表明，大麻衍生物可能会改善精神分裂症特异性认知功能障碍，且没有目前其他药物具有的任何副作用。

只有韩国人会得的精神病 医学界正式承认“火病”

最近韩国媒体一篇题为《只有韩国人才患的疾病》的新闻成为话题。文章称，世界上存在唯独韩国人才患的疾病，而美国精神医学学会也正式承认了该疾病。

JAMA Psychiatry：利拉鲁肽可降低抗精神病药导致的心血管风险

利拉鲁肽可显著改善服用氯氮平或奥氮平的精神病患者的糖耐量水平、体重和心脏代谢紊乱的病情